1598 studies found for:    Open Studies | "Lymphatic Diseases"
Show Display Options
Rank Status Study
21 Recruiting Lymphedema Progression Screening Using MRI
Conditions: Lymphedema;   Breast Cancer
Intervention: Procedure: Manual lymphatic drainage therapy
22 Not yet recruiting A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults
Condition: Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia
Interventions: Drug: Nilotinib;   Drug: Methotrexate;   Drug: Aracytine (Ara C);   Drug: Granulocyte Colony-Stimulating Factor (G-CSF);   Drug: Depomedrol;   Drug: Dexamethasone;   Drug: Vincristine;   Drug: Imatinib;   Drug: 6 Mercaptopurine (6MP)
23 Not yet recruiting A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Polatuzumab Vedotin;   Drug: Venetoclax
24 Not yet recruiting Study of Histone Deacetylase Inhibitor (HDACi) Abexinostat, Combined With Ibrutinib, in Subjects With Relapsed/Refractory (R/R) Lymphomas
Conditions: Follicular Lymphoma;   Diffuse Large B-cell Lymphoma;   Peripheral T-cell Lymphoma
Interventions: Drug: Abexinostat;   Drug: Ibrutinib
25 Not yet recruiting Effect of IFN-γ on Innate Immune Cells
Condition: Chronic Granulomatous Disease
Intervention: Drug: Administration of drug (Interferon-gamma 1-b) subcutaneously
26 Not yet recruiting Effectiveness of Fluoroscopy-guided MLD for Treatment of BCRL
Conditions: Breast Neoplasm;   Lymphedema
Interventions: Other: Information;   Other: Skin care;   Other: Compression therapy;   Other: Fluoroscopy-guided MLD;   Other: Traditional MLD;   Other: Placebo MLD
27 Recruiting Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement
Conditions: Erdheim-Chester Disease;   Langerhans Cell Histiocytosis;   Histiocytic Disorders
Interventions: Radiation: F-choline PET Scan;   Device: FDG-PET;   Procedure: biopsy
28 Not yet recruiting A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor
Condition: Thymic Epithelial Tumors
Intervention: Drug: Pembrolizumab
29 Not yet recruiting Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
Condition: Lymphoma
Interventions: Drug: Duvelisib;   Drug: Rituximab;   Drug: R-CHOP;   Drug: Prednisone
30 Recruiting Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission
Conditions: Acute Myeloid Leukemia;   Acute Lymphoid Leukemia
Interventions: Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: CXCR4 Antagonist;   Procedure: Hematopoietic Stem Cell Transplantation
31 Not yet recruiting Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Ibrutinib
32 Recruiting Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib
Condition: Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Interventions: Drug: Alectinib;   Drug: Docetaxel;   Drug: Pemetrexed
33 Not yet recruiting Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL
Conditions: Follicular Lymphoma (FL),;   Mantle Cell Lymphoma (MCL)
Interventions: Drug: BCL201;   Drug: Idelalisib
34 Not yet recruiting Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
Condition: Hodgkins Lymphoma
Intervention: Biological: Avelumab
35 Recruiting A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma
Condition: Relapsed/Refractory Mantle Cell Lymphoma
Intervention: Biological: KTE-C19
36 Not yet recruiting A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Obinutuzumab;   Drug: Polatuzumab Vedotin
37 Recruiting 18F-FSPG PET/CT for Cancer Patients on Therapy
Conditions: B-Cell Neoplasm;   Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Renal Cell Cancer;   Progesterone Receptor Negative;   Stage III Mesothelioma;   Stage III Renal Cell Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Mesothelioma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Triple-Negative Breast Carcinoma
Interventions: Procedure: Computed Tomography;   Radiation: Fluorine F 18 L-glutamate Derivative BAY94-9392;   Procedure: Positron Emission Tomography;   Procedure: Magnetic Resonance Imaging
38 Recruiting Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
Condition: Lymphoma
Intervention: Drug: duvelisib
39 Recruiting Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas
Condition: Relapsed Cutaneous T Cell Lymphom
Intervention: Drug: Mitoxantrone HCL Liposome Injection
40 Recruiting Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma
Condition: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Interventions: Drug: Bendamustine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: MPDL3280A;   Drug: Obinutuzumab;   Drug: Prednisone;   Drug: Vincristine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years